Timing clarification: IQVIA is scheduled to report today, Tuesday, July 28, 2026, before the market opens, followed by its earnings call at 9:00 a.m. ET. The date supplied—July 28—is not tomorrow.
IQVIA enters the report with improving operating momentum but a substantially higher investor bar than it faced three months ago. First-quarter results showed accelerating organic growth in both major segments, strengthening clinical-demand indicators, and early commercial traction from the company’s healthcare-specific AI offerings.
The stock closed July 27 at $213.26, approximately 21% above its May 5 closing price following the Q1 report, though still down about 5% year to date. At roughly 16.7 times the midpoint of 2026 adjusted EPS guidance, the valuation is not demanding in isolation, but the recent recovery means another merely acceptable quarter may not be enough.
The most important issue is unlikely to be whether adjusted EPS beats by a few cents. Investors need evidence that:
| Metric | Q2 2026 guidance | Midpoint | Q2 2025 actual | Midpoint growth |
|---|---|---|---|---|
| Revenue | $4.280B–$4.340B | $4.310B | $4.017B | 7.3% |
| Adjusted EBITDA | $955M–$975M | $965M | $910M | 6.0% |
| Adjusted diluted EPS | $2.98–$3.08 | $3.03 | $2.81 | 7.8% |
The implied adjusted EBITDA margin at the midpoint is approximately 22.4%, almost unchanged from Q1’s 22.5%. Management previously said productivity should allow reported margin trends to improve as the year progresses.
| Metric | FY2026 guidance | Midpoint | Implied growth at midpoint |
|---|---|---|---|
| Revenue | $17.150B–$17.350B | $17.250B | 5.8% |
| Adjusted EBITDA | $3.975B–$4.025B | $4.000B | 5.6% |
| Adjusted diluted EPS | $12.65–$12.95 | $12.80 | 7.4% |
IQVIA raised EPS guidance by $0.10 after Q1 but left revenue and EBITDA guidance unchanged. A second consecutive beat without any improvement in revenue or EBITDA guidance could raise questions about conservatism versus limited incremental operating upside.
IQVIA’s Research & Development Solutions segment reported:
The headline Q1 book-to-bill figure understated underlying demand because reimbursable pass-through bookings were unusually low. Management said service-fee bookings grew strongly both year over year and sequentially, cancellations were normal, and a normal pass-through mix would have produced a book-to-bill closer to roughly 1.15x.
More important than the reported book-to-bill ratio:
A reported Q2 book-to-bill above approximately 1.1x, paired with continued high-single-digit growth in next-12-month backlog conversion, would support the view that clinical revenue growth can accelerate. A weak ratio may still be explainable by pass-through timing, but investors will be less forgiving if service-fee bookings or near-term backlog conversion also deteriorate.
Backlog size alone is not enough. Clinical contracts can take several years to convert, can be delayed, and are often terminable on short notice. The $8.9 billion near-term conversion figure is therefore a better indicator of the next several quarters than the total $34.2 billion backlog.
Commercial Solutions was the standout business in Q1:
The recast Q2 2025 revenue comparison is $1.651 billion. Investors should focus on organic growth rather than reported growth because currency and acquisitions contributed materially in Q1.
A result near 5% organic growth would validate management’s argument that commercial spending is recovering after several years of client caution. Particular attention should be paid to:
Commercial Solutions is strategically important because it is more diversified than the clinical business and provides the clearest near-term avenue for IQVIA to monetize its proprietary healthcare data.
Management disclosed in Q1 that IQVIA had:
The company argues that AI is a net demand creator rather than a threat. In Commercial Solutions, it can create new analytics and data-foundation offerings. In R&DS, agents can reduce study start-up time, automate documentation, improve site selection, and limit errors and rework.
The adoption figures are impressive, but investors now need more economically useful disclosure:
The best outcome would be evidence that AI is simultaneously producing incremental commercial revenue and clinical delivery efficiencies. More agent-count updates without corresponding revenue, bookings, or margin evidence would be less meaningful.
Q1 revenue grew 8.4%, while adjusted EBITDA grew only 5.5%. Both reported segments also experienced year-over-year margin pressure:
Management maintained that underlying operational margins improved and that productivity more than offset adverse business mix, with currency and pass-through effects obscuring the improvement.
Q2 should help validate that claim. Investors should look for:
A revenue beat driven primarily by acquisitions, currency, or zero-margin pass-through revenue would be lower quality than a smaller beat accompanied by organic growth and margin expansion.
At the midpoint, full-year guidance requires approximately:
That translates to second-half growth of roughly 4% for revenue, 5% for adjusted EBITDA, and 7% for adjusted EPS versus the comparable 2025 period. Those requirements appear achievable if commercial momentum persists and clinical backlog converts as expected.
The quality of any guidance increase matters more than its size. A revenue/EBITDA raise would indicate stronger operations; an EPS-only raise may primarily reflect a lower share count, taxes, or financing assumptions.
IQVIA finished Q1 with:
In June, a subsidiary issued €950 million of 4.625% senior notes due 2033, with proceeds intended to refinance existing debt.
IQVIA’s free-cash-flow generation supports buybacks, but leverage remains significant and interest expense rose to $192 million in Q1 from $165 million a year earlier. Initial 2026 guidance already incorporated an approximately $80 million annual increase in interest expense related to financing and refinancing activity.
Investors should watch:
Repurchases have contributed materially to EPS growth: Q1’s diluted share count fell about 4% year over year. That is beneficial, but investors should distinguish share-count-driven EPS growth from operating profit growth.
| Scenario | What it could look like |
|---|---|
| Bull case | Revenue and EPS exceed the high ends of guidance; service-fee bookings remain strong; book-to-bill exceeds roughly 1.1x; near-term backlog conversion grows high single digits; Commercial organic growth stays near 5%; revenue and EBITDA guidance increase. |
| Base case | Results land around or modestly above guidance; bookings normalize after Q1’s pass-through distortion; Commercial remains healthy; full-year revenue and EBITDA guidance are maintained, with perhaps another small EPS increase. |
| Bear case | R&DS organic growth slows, service bookings weaken, or cancellations rise; next-12-month backlog conversion decelerates; Commercial Q1 strength proves temporary; margins remain under pressure; management lowers or narrows guidance unfavorably. |
The setup is constructive but no longer low-expectation. IQVIA’s Q1 report presented a credible recovery narrative: accelerating organic growth, improving clinical-demand indicators, record commercial pipelines, strong cash flow, and broad AI adoption. The stock’s subsequent rally indicates that investors have begun to price in that improvement.
For this report, the highest-value indicators are:
A small EPS beat driven by repurchases would not, by itself, settle the investment debate. A strong report would show that IQVIA’s underlying demand recovery is broadening and that faster revenue growth can finally translate into stronger operating leverage.
This preview is based on information available before the Q2 2026 release and is not investment advice.